The symposium titled: "Managing CKD, Diabetes
& CVD: Is epigenetics a new way forward?" at the ERA-EDTA
Congress highlights BET-inhibition and apabetalone in addressing
the significant unmet medical need in chronic kidney disease and
cardiovascular disease.
CALGARY, May 31, 2017 /PRNewswire/ - Resverlogix
Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced
that on Monday, June 5, 2017, at the
European Renal Association – European Dialysis and Transplant
Association (ERA-EDTA) Congress in Madrid, Spain, the Company will host a
symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics
a new way forward?"
"The presentations at the ERA-EDTA Congress symposium highlight
the opportunity and need for a novel approach to reduce risk in
kidney and cardiovascular disease, and demonstrate the important
role for epigenetics in the underlying pathology of these
diseases," commented Donald
McCaffrey, President and CEO. "Based on its mechanism,
emerging data illustrates that apabetalone has the potential to
address the significant unmet medical need in this patient
population. Importantly, the Company's planned Phase 2a trial in
kidney dialysis patients was recently approved to proceed by the
FDA. The trial is designed to evaluate the efficacy, safety, and
pharmacokinetics of apabetalone in patients with end-stage renal
disease on dialysis. More broadly, the Company's chronic kidney
disease program, with apabetalone, is aimed at assessing the
cardiovascular risk reducing potential, in addition to any improved
kidney function, observed in prior Phase 2 trials. Ultimately, we
believe apabetalone will improve health outcomes for this high-risk
patient population."
The speakers and agenda are as follows:
Introduction
- Vincent M Brandenburg, MD – Aachen, Germany
The high risk diabetes patient: What is the need for novel
approaches to reduce cardiovascular and renal risk?
- Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain
Epigenetics as a novel strategy in cardiovascular and renal risk
reduction: A closer look at BET as a pathway for inhibition
- Marta Ruiz-Ortega – Foundación
Jiménez Diaz, Madrid, Spain
BET inhibition in renal and cardiovascular disease: What is the
clinical roadmap?
- Kamyar Kalantar-Zadeh, MD – UC
Irvine School of Medicine, Irvine,
USA
Discussion & summary
- Carmine Zoccali, MD – Reggio
Cal, Italy
These symposium presentations will be made available at:
http://pace-cme.org/bet-inhibition/ shortly after the live
event.
Resverlogix will also present two posters and one oral
presentation at the congress as follows:
Oral
Presentation:
|
|
|
|
Date:
|
Monday, June 5,
2017
|
Time:
|
8:00 – 10:00
CET
|
Session Title:
|
Experimental Renal
Pathology
|
|
|
Presentation Title:
|
Apabetalone
(RVX-208) Impacts Key Biomarkers and Pathways Associated with
Chronic Kidney Disease in Patients with Severe Renal
Impairment
|
|
|
Posters:
|
|
|
|
Date:
|
Sunday June 4,
2017
|
Time:
|
9:30 - 10:45
CET
|
Poster presentation
number:
|
SP425
|
|
|
Poster
Title:
|
Effects of
Apabetalone (RVX-208) on Serum Albumin in Subjects with CVD,
Diabetes and Chronic Kidney Disease; A Post-hoc Analysis of the
ASSURE and SUSTAIN Clinical Trials
|
|
|
Date:
|
Monday, June 5,
2017
|
Time:
|
9:30 - 10:45
CET
|
Poster presentation
number:
|
MP092
|
|
|
Poster
Title:
|
Apabetalone, a
Bromodomain and Extraterminal Protein Inhibitor, Decreases Key
Factors in Vascular Calcification in vitro and in Clinical
Trials
|
The two posters will be made available on the Resverlogix
website HERE at 7:00 AM MT on
Monday, June 5th,
2017.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a
first-in-class, small molecule that is a selective BET (bromodomain
and extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease (CVD), diabetes
mellitus (DM), chronic kidney disease, dialysis, Alzheimer's
disease, Fabry disease, other orphan diseases, and peripheral
artery disease, while maintaining a well described safety profile.
Apabetalone is the only selective BET bromodomain inhibitor in
human clinical trials. Apabetalone is currently in a Phase 3 trial,
BETonMACE, in high-risk CVD patients with type 2 DM and low
high-density lipoprotein (HDL), and is expected to be initiated in
a Phase 2a kidney dialysis trial designed to evaluate biomarker
changes and safety parameters in up to 30 patients with end-stage
renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter:
@Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on
our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information relating to the potential role of apabetalone in the
treatment of cardiovascular disease, CVD, DM, chronic kidney
disease, CKD, end-stage renal disease treated with hemodialysis,
Alzheimer's disease, vascular calcification, and Orphan diseases.
Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and
risk factors including those discussed in our Annual Information
Form and most recent MD&A which are incorporated herein by
reference and are available through SEDAR at www.sedar.com. The
forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE Resverlogix Corp.